Marcel van Gelderen - Concepedia

Author

Marcel van Gelderen

Astellas Pharma (Netherlands)

Also Known As

Amit Roy, Marcel Van Gelderen, Marcel van Gelderen

Publications

523

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (Netherlands)Astellas Pharma (Japan)PharmAccess Group Astellas Pharma (United States)

About

Marcel van Gelderen is an author at Astellas Pharma (Netherlands) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	304
2	Public Health	1	1	22
3	Biochemistry	1	1	39
4	Hepatology	1	1	30
5	Nephrology	1	1	30

Marcel van Gelderen

Publications

517

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women Walter Krauwinkel, Jan van Dijk, Marloes Schaddelee, Clinical Therapeutics Elderly MenPharmacological StudyPharmacologyClinical PharmacologyExperimental Pharmacology	2012	96
Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers Shin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, Drug Metabolism and Disposition	2012	62
Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder Charlotte Eltink, Jennifer Lee, Marloes Schaddelee, International Journal of Clinical Pharmacology and Therapeutics	2012	54
Development and validation of LC–MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study Raymond van Teijlingen, John Meijer, Shin Takusagawa, Journal of Chromatography B MedicineLc–ms/ms MethodsMass SpectrometryHuman PlasmaAnalytical Chemistry	2012	48
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol Walter Krauwinkel, James Dickinson, Marloes Schaddelee, European Journal of Drug Metabolism and Pharmacokinetics Molecular PharmacologyPharmacological StudyDrug DiscoveryPhysiologyPharmacology	2013	45
Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist Jennifer Lee, Selina Moy, John Meijer, Clinical Drug Investigation Molecular Pharmacologyβ3-Adrenoceptor AgonistBiochemistryMedicinePhysiology	2013	39
Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron James Dickinson, Michaelene Lewand, Taiji Sawamoto, Clinical Drug Investigation Renal FunctionHepatologyLiver PhysiologyPharmacologyHepatic Impairment	2012	30
Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies Hiromi Iitsuka, Tomoaki Tokuno, Yoko Amada, Clinical Drug Investigation	2013	30
An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron‐Induced Cardiovascular Effects Marcel van Gelderen, Matthias Stölzel, John Meijer, The Journal of Clinical Pharmacology	2017	25
Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives Monique Groen-Wijnberg, Jan van Dijk, Walter Krauwinkel, European Journal of Drug Metabolism and Pharmacokinetics Drug InteractionsOral ContraceptivesOral ContraceptivePharmacologyPharmacotherapy	2016	24

Page 1